Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, ...

Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

NEW YORK – CRISPR Therapeutics and Sirius Therapeutics have inked a deal valued at up to $95 million to develop and commercialize small interfering RNA therapies, starting with a treatment for ...

CRISPR Therapeutics CRSP announced that it has entered into a collaboration deal with San Diego-based privately held company, Sirius Therapeutics, for developing and commercializing novel siRNA ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

-Under the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to ...

“We are excited to partner with Sirius, and broaden our ... (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation ...